Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-m9kch Total loading time: 0 Render date: 2024-06-01T01:23:23.228Z Has data issue: false hasContentIssue false

Chapter 44 - Checkpoint Inhibitor Immune Related Adverse Events

from Section 5 - Lymphatic System

Published online by Cambridge University Press:  10 August 2023

Monica Kathleen Wattana
Monica Kathleen Wattana
Affiliation:
University of Texas, MD Anderson Cancer Center
Get access

Summary

Overview of toxicities related to immunotherapy agents, and other complications in the lymphatic system such as tumor lysis, hyperviscosity syndrome, graft vs host disease, and neutropenic fever

Keywords

tumor lysisacute leukemianeutropenic feverdifferentiation syndrome
Type
Chapter
Information
Pocket Guide to Oncologic Emergencies , pp. 177 - 184
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Albarrán, V, Chamorro, J, Rosero, DI, Saavedra, C, Soria, A, Carrato, A, Gajate, P. Neurologic toxicity of immune checkpoint inhibitors: A review of literature. Frontiers in Pharmacology. 2022; 13. Doi: 10.3389/fphar.2022.774170.Google Scholar
Cappelli, LC, Gutierrez, AK, Bingham, CO III, Shah, AA. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature. Arthritis Care and Research. 2017;69(11):1751–1763. Doi: 10.1002/acr.23177.CrossRefGoogle ScholarPubMed
Castillo, RM, Sandefur, BJ, Finch, AS, Richter, MD, Thanarajasingam, U. Clinical presentations and outcomes of patients receiving immune checkpoint inhibitors presenting to the emergency department. Mayo Clinic Proceedings: Innovations, Quality & Outcomes. 2021;5(6):1029–1035. Doi:10.1016/j.mayocpiqo.2021.09.007.Google ScholarPubMed
Del Rivero, J, Cordes, LM, Klubo‐Gwiezdzinska, J, Madan, RA, Nieman, LK, Gulley, JL. Endocrine-related adverse events related to immune checkpoint inhibitors: Proposed algorithms for management. The Oncologist. 2020;25(4):290–300. Doi: 10.1634/theoncologist.2018-0470.CrossRefGoogle ScholarPubMed
Hryniewicki, AT, Wang, C, Shatsky, RA, Coyne, CJ. Management of immune checkpoint inhibitor toxicities: A review and clinical guideline for emergency physicians. Journal of Emergency Medicine. 2018 Oct;55(4):489–502. Doi: 10.1016/j.jemermed.2018.07.005. Epub 2018 Aug 16. PMID: 30120013.CrossRefGoogle ScholarPubMed
Lauwyck, J, Beckwée, A, Santens, A, Schwarze, JK, Awada, G, Vandersleyen, V, Aspeslagh, S, Neyns, B. C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting. Melanoma Research. 2021 Aug 1;31(4):371–377. Doi: 10.1097/CMR.0000000000000748. PMID: 34054056.CrossRefGoogle ScholarPubMed
Muntyanu, A, Netchiporouk, E, Gerstein, W, Gniadecki, R, Litvinov, IV. Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: A dermatology perspective on management . Journal of Cutaneous Medicine and Surgery. 2021 Jan‒Feb;25(1):59–76. Doi: 10.1177/1203475420943260. Epub 2020 Aug 3. PMID: 32746624.CrossRefGoogle ScholarPubMed
Nso, N, Antwi-Amoabeng, D, Beutler, BD, et al. Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis. World Journal of Cardiology. 2020;12(11):584–598. Doi: 10.4330/wjc.v12.i11.584.CrossRefGoogle ScholarPubMed
Rapoport, BL, Shannon, VR, Cooksley, T, Johnson, DB, Anderson, L, Blidner, AG, Tintinger, GR, Anderson, R. Pulmonary toxicities associated with the use of immune checkpoint inhibitors: An update from the immuno-oncology subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer. Frontiers in Pharmacology. 2021. Doi: 10.3389/fphar.2021.743582.CrossRefGoogle Scholar
Schneider, BJ, Naidoo, J, Santomasso, BD, Lacchetti, C, Adkins, S, Anadkat, M, Atkins, MB, Brassil, KJ, Caterino, JM, Chau, I, Davies, MJ, Ernstoff, MS, Fecher, L, Ghosh, M, Jaiyesimi, I, Mammen, JS, Naing, A, Nastoupil, LJ, Phillips, T, Porter, LD, Reichner, CA, Seigel, C, Song, JM, Spira, A, Suarez-Almazor, M, Swami, U, Thompson, JA, Vikas, P, Wang, Y, Weber, JS, Funchain, P, Bollin, K. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. Journal of Clinical Oncology. 2021 Dec 20;39(36):4073–4126. Doi: 10.1200/JCO.21.01440. Epub 2021 Nov 1. Erratum in: Journal of Clinical Oncology. 2022 Jan 20;40(3):315. PMID: 34724392.CrossRefGoogle ScholarPubMed
Shah, M, Rajha, E, DiNardo, C, Muckey, E, Wierda, WG, Yeung, SJ. Adverse events of novel therapies for hematologic malignancies: What emergency physicians should know. Annals of Emergency Medicine. 2020 Feb;75(2):264–286. Doi: 10.1016/j.annemergmed.2019.07.015. Epub 2019 Sep 24. PMID: 31561995.CrossRefGoogle ScholarPubMed
Trinh, S, Le, A, Gowani, S, La-Beck, NM. Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: A minireview of current clinical guidelines. Asia-Pacific Journal of Oncology Nursing. 2019; 6(2):154–160. Doi: 10.4103/apjon.apjon_3_19.CrossRefGoogle ScholarPubMed
Yeung, SJ, Qdaisat, A, Chaftari, P, Lipe, D, Merlin, J, Rajha, E, Wechsler, A, Sandoval, M, Viets, J, Al-Breiki, A, Shah, M, Pandey, R, Kamal, M, Khattab, O, Toale, K, Wattana, M, Elsayem, A, Gaeta, S, Brock, P, Reyes-Gibby, C, Alagappan, K. Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department. Journal of the American College of Emergency Physicians Open. 2020 Aug 30;1(6):1637–1659. Doi: 10.1002/emp2.12209. PMID: 33392573; PMCID: PMC7771833.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×